124 related articles for article (PubMed ID: 30963174)
1. β-hCG-induced mutant BRCA1 ignites drug resistance in susceptible breast tissue.
Sengodan SK; Hemalatha SK; Nadhan R; Somanathan T; Mathew AP; Chil A; Kopczynski J; Nair RS; Kumar JM; Srinivas P
Carcinogenesis; 2019 Nov; 40(11):1415-1426. PubMed ID: 30963174
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 regulation on β-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
Sengodan SK; Nadhan R; Nair RS; Hemalatha SK; Somasundaram V; Sushama RR; Rajan A; Latha NR; Varghese GR; Thankappan RK; Kumar JM; Chil A; Anilkumar TV; Srinivas P
Oncogenesis; 2017 Sep; 6(9):e376. PubMed ID: 28869585
[TBL] [Abstract][Full Text] [Related]
3. Proteomic Profiling of β-hCG-Induced Spheres in BRCA1 Defective Triple Negative Breast Cancer Cells.
Sengodan SK; Rajan A; Hemalatha SK; Nadhan R; Jaleel A; Srinivas P
J Proteome Res; 2018 Jan; 17(1):276-289. PubMed ID: 29028349
[TBL] [Abstract][Full Text] [Related]
4. S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability.
Buckley NE; D'Costa Z; Kaminska M; Mullan PB
Cell Death Dis; 2014 Feb; 5(2):e1070. PubMed ID: 24556685
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human chorionic gonadotropin induces signaling pathways towards cancer prevention in the breast of BRCA1/2 mutation carriers.
Su Y; Dang NM; Depypere H; Santucci-Pereira J; Gutiérrez-Díez PJ; Kanefsky J; Janssens JP; Russo J
Eur J Cancer Prev; 2023 Mar; 32(2):126-138. PubMed ID: 35881946
[TBL] [Abstract][Full Text] [Related]
6. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 promoter hypermethylation in human placenta: a hidden link with β-hCG expression.
Nadhan R; Vaman JV; Sengodan SK; Hemalatha SK; Chellappan N; Sadasivan S; Pasuthottiyil Varkey A; Yesodharan S; Raji Sathyanpillai K; Bhuvaneswari Venugopal AK; Prameelakumari Sreenivasan S; Rajan A; Latha NR; Varghese GR; Thankappan R; Achyutuni S; Sreekumar Usha JD; Vijayamma Anilkumar T; Srinivas P
Carcinogenesis; 2020 Jul; 41(5):611-624. PubMed ID: 31219560
[TBL] [Abstract][Full Text] [Related]
8. Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumors.
Choi EK; Lim JA; Kim JK; Jang MS; Kim SE; Baek HJ; Park EJ; Kim TH; Deng CX; Wang RH; Kim SS
Exp Mol Med; 2018 Oct; 50(10):1-16. PubMed ID: 30327455
[TBL] [Abstract][Full Text] [Related]
9. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
Wang J; Ding Q; Fujimori H; Motegi A; Miki Y; Masutani M
Oncotarget; 2016 Feb; 7(7):7701-14. PubMed ID: 26713604
[TBL] [Abstract][Full Text] [Related]
10. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
[TBL] [Abstract][Full Text] [Related]
11. Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
Mamon HJ; Dahlberg W; Azzam EI; Nagasawa H; Muto MG; Little JB
Int J Radiat Biol; 2003 Oct; 79(10):817-29. PubMed ID: 14630541
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer cell response to genistein is conditioned by BRCA1 mutations.
Privat M; Aubel C; Arnould S; Communal Y; Ferrara M; Bignon YJ
Biochem Biophys Res Commun; 2009 Feb; 379(3):785-9. PubMed ID: 19126406
[TBL] [Abstract][Full Text] [Related]
13. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
14. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
[TBL] [Abstract][Full Text] [Related]
15. Molecular trail for the anticancer behavior of a novel copper carbohydrazone complex in BRCA1 mutated breast cancer.
Nair RS; Potti ME; Thankappan R; Chandrika SK; Kurup MR; Srinivas P
Mol Carcinog; 2017 May; 56(5):1501-1514. PubMed ID: 28052399
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
Promkan M; Liu G; Patmasiriwat P; Chakrabarty S
Int J Cancer; 2009 Dec; 125(12):2820-8. PubMed ID: 19551867
[TBL] [Abstract][Full Text] [Related]
17. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 suppresses the expression of survivin and promotes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in human breast cancer cells.
Promkan M; Liu G; Patmasiriwat P; Chakrabarty S
Cell Calcium; 2011 Feb; 49(2):79-88. PubMed ID: 21296416
[TBL] [Abstract][Full Text] [Related]
19. Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.
Xu X; Lv YG; Yan CY; Yi J; Ling R
Biochem Biophys Res Commun; 2016 Oct; 479(4):893-900. PubMed ID: 27693788
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 suppresses osteopontin-mediated breast cancer.
El-Tanani MK; Campbell FC; Crowe P; Erwin P; Harkin DP; Pharoah P; Ponder B; Rudland PS
J Biol Chem; 2006 Sep; 281(36):26587-601. PubMed ID: 16807234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
